These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12568641)

  • 1. Selegiline-transdermal--Somerset: Emsam.
    Drugs R D; 2003; 4(1):59-60. PubMed ID: 12568641
    [No Abstract]   [Full Text] [Related]  

  • 2. Transdermal selegiline (Emsam).
    Med Lett Drugs Ther; 2006 May; 48(1235):41-2. PubMed ID: 16770292
    [No Abstract]   [Full Text] [Related]  

  • 3. Possible serotonin syndrome arising from an interaction between nortriptyline and selegiline in a lady with parkinsonism.
    Hinds NP; Hillier CE; Wiles CM
    J Neurol; 2000 Oct; 247(10):811. PubMed ID: 11127542
    [No Abstract]   [Full Text] [Related]  

  • 4. Selegiline transdermal system Somerset.
    Mahmood I
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transdermal selegiline: a novel MAOI formulation for depression.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2006 Jul; 44(7):9-12. PubMed ID: 17310829
    [No Abstract]   [Full Text] [Related]  

  • 6. Administration of selegiline is not associated with visual hallucinations in advanced Parkinson's disease patients.
    Papapetropoulos S; Argyriou AA
    Parkinsonism Relat Disord; 2005 Jun; 11(4):265-6; author reply 267. PubMed ID: 15878591
    [No Abstract]   [Full Text] [Related]  

  • 7. Transdermal selegiline: new opportunity for managing depression.
    Tobe EH
    J Am Osteopath Assoc; 2008 Feb; 108(2):85-6. PubMed ID: 18303066
    [No Abstract]   [Full Text] [Related]  

  • 8. Sublingual selegiline: new formulation. New formulation: new risk of oral adverse effects.
    Prescrire Int; 2003 Oct; 12(67):179. PubMed ID: 14619897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of selegiline with cold medications.
    Jacob JE; Wagner ML; Sage JI
    Ann Pharmacother; 2003 Mar; 37(3):438-41. PubMed ID: 12639177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline transdermal system: a novel treatment option for major depressive disorder.
    Nandagopal JJ; DelBello MP
    Expert Opin Pharmacother; 2009 Jul; 10(10):1665-73. PubMed ID: 19527191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Patients taking selegeline may have received more levodopa than necessary.
    Olanow CW; Godbold JH; Koller W
    BMJ; 1996 Mar; 312(7032):702-3; author reply 704-5. PubMed ID: 8597746
    [No Abstract]   [Full Text] [Related]  

  • 12. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
    Tobin M
    Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
    [No Abstract]   [Full Text] [Related]  

  • 13. A critical appraisal of the selegiline transdermal system for major depressive disorder.
    Bied AM; Kim J; Schwartz TL
    Expert Rev Clin Pharmacol; 2015; 8(6):673-81. PubMed ID: 26427518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
    Thase ME
    J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
    [No Abstract]   [Full Text] [Related]  

  • 15. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine.
    Preskorn SH
    J Psychiatr Pract; 2006 May; 12(3):168-72. PubMed ID: 16732136
    [No Abstract]   [Full Text] [Related]  

  • 16. A new way to deliver psychiatric meds.
    Levin-Epstein M
    Behav Healthc; 2006 Aug; 26(8):22-3. PubMed ID: 16961036
    [No Abstract]   [Full Text] [Related]  

  • 17. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
    Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
    J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
    Bodkin JA; Amsterdam JD
    Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.